Regorafenib

CAT#: H202436

CAS#: 755037-03-7

Description: Regorafenib, also known as BAY 73-4506 ; is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. Regorafenib demonstrated to increase the overall survival of patients with metastatic colorectal cancer

img

Synthetic Routes

Regorafenib - Synthetic Route 1

Regorafenib route01

Synthetic reference

Du, Fangyu; Zhou, Qifan; Shi, Yajie; Yu, Miao; Sun, Wenjiao; Chen, Guoliang. A new pathway via intermediate 4-​amino-​3-​fluorophenol for the synthesis of regorafenib. Synthetic Communications. Volume 49. Issue 4. Pages 576-586. Journal; Online Computer File. (2019).

Regorafenib - Synthetic Route 2

Regorafenib route02

Synthetic reference

Research on Chemical Intermediates Volume 42 Issue 4 Pages 3209-3218 Journal; Online Computer File 2016

Regorafenib - Synthetic Route 3

Regorafenib route03

Synthetic reference

Liu, Zhenteng; Liu, Xinquan; Wei, Shuhong; Gao, Ruizhao. Method for preparing regorafenib. Assignee Shandong Luoxin Pharmaceutical Group Hengxin Pharmaceutical Co., Ltd., Peop. Rep. China. CN 108558747. (2018).

Regorafenib - Synthetic Route 4

Regorafenib route04

Synthetic reference

: Oruganti, Srinivas; Rapolu, Rajesh Kumar. Processes for the preparation of diphenyl urea derivatives and novel intermediates thereof. Assignee Dr. Reddy's Laboratories Limited, India. IN 2014CH01136. (2016).

Regorafenib - Synthetic Route 5

Regorafenib route05

Synthetic reference

Sun, Song; Li, Qiang; Hou, Xiaolong. Preparation method of Regorafenib. Assignee Shandong Luoxin Pharmaceutical Group Co., Ltd., Peop. Rep. China. CN 105330600. (2016).

Regorafenib - Synthetic Route 6

Regorafenib route06

Synthetic reference

Xu, Qiang; Huang, Shuang; Yang, Jian; Wang, Ping; Xia, Bin; Qian, Gang. Process for the preparation of regorafenib. Assignee Jiangsu Zhongbang Pharmaceutical Co., Ltd., Peop. Rep. China. CN 105130887. (2015).